Connor Clark & Lunn Investment Management Ltd. Lowers Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Connor Clark & Lunn Investment Management Ltd. trimmed its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 30.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,172,974 shares of the company's stock after selling 523,901 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.54% of Hims & Hers Health worth $28,363,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of HIMS. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the 4th quarter worth $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after purchasing an additional 1,100 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after buying an additional 1,413 shares in the last quarter. US Bancorp DE lifted its stake in shares of Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after buying an additional 1,508 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at $48,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HIMS shares. Leerink Partners lifted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Bank of America restated an "underperform" rating and set a $21.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Truist Financial lifted their target price on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a research note on Wednesday, February 26th. Citigroup restated a "sell" rating and set a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Finally, TD Cowen reaffirmed a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Hims & Hers Health has an average rating of "Hold" and an average target price of $37.23.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 4,152 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares of the company's stock, valued at approximately $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Michael Chi sold 17,303 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $48.14, for a total transaction of $832,966.42. Following the sale, the insider now directly owns 193,601 shares of the company's stock, valued at $9,319,952.14. This represents a 8.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 969,191 shares of company stock valued at $34,005,375. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Up 5.0 %

Hims & Hers Health stock traded up $1.56 during mid-day trading on Friday, reaching $33.10. 17,052,310 shares of the company's stock traded hands, compared to its average volume of 13,517,903. The company has a market cap of $7.35 billion, a price-to-earnings ratio of 75.24 and a beta of 1.37. The stock has a 50 day moving average of $38.49 and a two-hundred day moving average of $28.13. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.